Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine
Authors' conclusion
Progression and development of GO were associated more with radioiodine treatment than with MMI treatment; GO may appear de novo or worsen years after radioiodine treatment but not after LT-MMI therapy.
Study context
- Population
- Patients with Graves disease treated for hyperthyroidism
- Participants
- 263 / 808 / 178
- Exposure
- Radioiodine vs short-term MMI vs long-term MMI
- Radioiodinen = 263
- Short-term MMIn = 808
- LT-MMIn = 178
- Outcome
- New onset or worsening of Graves orbitopathy (GO)
- Follow-up
- Median 159 months
Main finding
As reported in the abstract
Worsening and de novo development of GO · >18 to 234 months
P < 0.037
Observational data: associations, not effects.
Further findings
Relapse, euthyroidism, hypothyroidism · end of follow-up Radioiodine 16%, 22%, 62% · Short-term MMI 59%, 36%, 5% · LT-MMI 18%, 80%, 2%
Relapse
Euthyroidism
Hypothyroidism
Graves orbitopathy (GO) in first 18 months of therapy
- Worsening of GO, significantly more frequent after radioiodine (P <.004)
- 11.5% vs 5.7%
- De novo GO, significantly more frequent after radioiodine (P <.004)
- 12.5% vs 9.8%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine. Endocr Pract. Published 14 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →